Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth ... year to $13.5 billion from $9.3 billion. Earnings per share came in at $4.99, underperforming Wall ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs ... who was attending boot camp five days a week, was at her thinnest — 160 pounds.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss ... of $5.01 per share.

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...